Sibutramin ile ilişkili özkıyım düşünceleriyle seyreden depresyon: İki olgu sunumu

Obezite giderek yaygınlığı artan, genel tıbbi morbiditenin yanı sıra psikosoyal yönü önemli olan bir bozukluktur. Tedavisinde farmakolojik ajanların kullanımına olan ilgi artmaktadır. Sibutramin 1997’de FDA’den bu amaçla onay almış, santral etkili serotonin, noradrenelin ve daha düşük düzeyde de dopamin geri alımını engelleyen bir β- feniletilamindir. Preklinik ve klinik çalışmalarda antidepresan etkinliği gösterilmişse de, bu etkinliği antiobezite etkisinin gerisinde kalmıştır. Bu yazıda antidepresan etkinliği olan bu ilacın kullanımı sonrasında engellenemeyen özkıyım düşünceleriyle başvuran iki depresyon olgusu sunulmuş; ayrıca literatürde sibutramine bağlı gelişen psikiyatrik bozukluklar gözden geçirilmiştir. Bu sunumda obezite ve antiobezite ilaçlarının psikiyatrik belirti ve bozukluklarıyla ilişkisine dikkatin çekilmesi amaçlanmıştır.

Anahtar Kelimeler:

İntihar etme, Obezite, Depresyon, Erişkin, Kadın

Sibutramine associated depression with suicide preoccupation: two case reports

Obesity which has medical morbidity and psychological components has an increasing prevalence rate. In recent years there is an increasing interest on pharmacological treatment of obesity. Sibutramine which was a β- feniletilamine derivative had serotonergic, noradrenergic and weak dopaminergic reuptake inhibitor was approved by FDA in 1997 in treatment of obesity. In preclinical and clinical studies it was shown that sibutramine had antidepressant effects but this was beyond its antiobesity effects. In this presentation we present two cases of depression with suicidal ideation which was induced by a drug with antidepressant properties. We reviewed the psychiatric conditions due to sibutramine. It was aimed in this presentation to show relation between psychiatric symptoms and disorders with obesity and antiobesity drugs.

Keywords:

Suicide, Obesity, Depression, Adult, Female,

PDF

___

1. O’Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and costeffectiveness of sibutramine in the management of obesity: a technology assessment. Healty Technol Assess 2002; 6:1-97.
2. Arrone LJ. Modern medical management of obesity: The role of pharmaceutical intervention. J Am Diet Assoc 1998; 98:23-26.
3. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. Geneva, World Health Organization, 2000; 894:1-253.
4. Brownel KD, Wadden TA. Psychological factors affecting medical conditions: Obesity. BJ Sadock, VA Sadock (eds.), Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, seventh ed., Vol 2, Philadelphia, Lippincott Williams & Wilkins, 2000, p.1787-1797.
5. Proietto J, Fam BC, Ainslie DA, Thornburn AW. Novel anti-obesity drugs. Expert Opin Invest Drugs 2000; 9:1317-1326.
6. Bays H, Dujovne C. Pharmacotherapy of obesity: currently marketed and upcoming agents. Am J Cardiovasc Drugs 2002; 2:145-253.
7. Stahl SM. Essential Psychopharmacology. Second ed., Cambridge, Cambridge University Press, 2000.
8. Reductil Prospektüs Bilgisi. Abbott Lab. 9. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 42. London, British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2001.
10. Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002; 53:318-325.
11. Sadock BJ, Sadock VA. Synopsis of Psychiatry. Ninth ed., Philadelphia, Lipincott Williams & Wilkins, 2003, p.584-585.
12. Taflinski T, Chojinacka J. Sibutramine associated psychotic episode. Am J Psychiatry 2000; 157:2057-2058.
13. Eker ÇM, Onat Ö, Pırıldar Ş, Özaşkınlı S. Sibutramin ile indüklenen bir mikst epizot olgusu. Klinik Psikofarmakoloji Bülteni 2003; 13:129-132.
14. Benazzi F. Organic hypomania secondary to sibutramine-citalopram interaction. J Clin Psychiatry 2002; 63:165.
15. Corderio Q, Vallada H. Sibutramine induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002; 5:283-284.
16. Nasr S. Sibutramine and panic attacks. Am J Psychiatry 2002; 159:1795.
17. Lester D. The concentration of neurotransmitter metaboites in the cerebrospinal fluid of suicidal individuals; a meta analysis. Pharmacopsychiatry 1995; 28:77-79.
18. Hegerl U. Antidepressants and suicidality. Eur Arch Psychiatry Clin Neurosci 2006; 256:199-200.
19. Patent SB. Major depressive episodes and diet pills. Expert Opin Pharmacother 2002; 3:1405-1409.